Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
<strong>Background/objective </strong>The aim of this study was to evaluate relative performance of composite measures in psoriatic arthritis and assess the impact of structural damage and functional disability on outcomes during ixekizumab treatment. <br><strong> Methods <...
Үндсэн зохиолчид: | Coates, LC, Smolen, JS, Mease, PJ, Husni, ME, Merola, JF, Lespessailles, E, Kishimoto, M, Macpherson, L, Bradley, AJ, Bolce, R, Helliwell, PS |
---|---|
Формат: | Journal article |
Хэл сонгох: | English |
Хэвлэсэн: |
BMJ Publishing Group
2022
|
Ижил төстэй зүйлс
Ижил төстэй зүйлс
-
Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis
-н: Josef S Smolen, зэрэг
Хэвлэсэн: (2022-11-01) -
Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials
-н: Coates, L, зэрэг
Хэвлэсэн: (2018) -
Quality of life improvements in patients with PsA who achieve remission or low disease activity targets: results from two clinical trials of ixekizumab at three years of treatment
-н: Coates, LC, зэрэг
Хэвлэсэн: (2021) -
Ixekizumab in the treatment of psoriatic arthritis
-н: Yu. L. Korsakova, зэрэг
Хэвлэсэн: (2024-12-01) -
Methotrexate in psoriasis and psoriatic arthritis
-н: Coates, L, зэрэг
Хэвлэсэн: (2020)